Clinical Research Directory
Browse clinical research sites, groups, and studies.
SIRT and Peri-immunotherapy : a New Concept
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC stage B or C). Although promising results have been observed in preliminary clinical trials, further research is needed to better understand the underlying mechanisms, optimize treatment protocols, and confirm the long-term efficacy and safety of this combined approach
Official title: Response Assessment for Advanced HCC of Combined SIRT and Immunotherapy Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2025-06-01
Completion Date
2026-07-01
Last Updated
2025-05-14
Healthy Volunteers
No
Interventions
Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization
Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT. \- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control
Atezolizumab ± Bevacizumab
Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.
Locations (1)
Hôpital Paul Brousse - Radiology Department
Villejuif, France